A Phase III, Open-label, Single-center Study to Describe the Immunogenicity and Safety of a Single Dose of MenACYW Conjugate Vaccine in Participants Aged 12 Months and Older in Vietnam
Latest Information Update: 28 May 2024
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
Most Recent Events
- 22 May 2024 Status changed from active, no longer recruiting to completed.
- 15 Mar 2024 Planned End Date changed from 5 Apr 2024 to 9 Apr 2024.
- 15 Mar 2024 Planned primary completion date changed from 8 Mar 2024 to 9 Apr 2024.